Skip to main content

 Related scientific articles (all)

Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.

Authors : Charette N, Vandeputte C, Ameye L, Bogaert CV, Krygier J, Guiot T, Deleporte A, Delaunoit T, Geboes K, Van Laethem JL, Peeters M, Demolin G, Holbrechts S, Flamen P, Paesmans M, Hendlisz A
Year : 2019
Journal : BMC Cancer
Volume : 19
Pages : 134

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tria

Authors : Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, Fornier M, Boer K, Bardia A, Wilson TR, Stout TJ, Hsu JY, Shi Y, Piccart M, Gnant M, Baselga J, de Azambuja E
Year : 2019
Journal : Lancet Oncol

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).

Authors : McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart-Gebhart M, Gradishar WJ, Chia S, Di Leo A, Malorni L
Year : 2019
Journal : Eur J Cancer
Volume : 114
Pages : 55-66

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.

Authors : Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart-Gebhart M, Sotiriou C, Arteaga CL
Year : 2019
Journal : Clin Cancer Res
Volume : 25
Pages : 1434

Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

Authors : Garaud S, Buisseret L, Solinas C, Gu-Trantien C, de Wind A, Van den Eynden G, Naveaux C, Lodewyckx JN, Boisson A, Duvillier H, Craciun L, Ameye L, Veys I, Paesmans M, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Year : 2019
Journal : JCI Insight
Volume : 5

Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer.

Authors : Curigliano G, de Azambuja E, Lenihan D, Calabrò MG, Cardinale D, Cipolla CM
Year : 2019
Journal : Oncologist

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

Authors : Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E
Year : 2019
Journal : J Natl Cancer Inst
Volume : 111
Pages : 86-94

EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.

Authors : Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG
Year : 2019
Journal : Future Oncol

Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer.

Authors : Lambertini M, Viglietti G, de Azambuja E
Year : 2019
Journal : Curr Opin Oncol
Volume : 31
Pages : 43-51

Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.

Authors : Kotecki N, Gombos A, Awada A
Year : 2019
Journal : Expert Rev Anticancer Ther
Pages : 1-8

Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine.

Authors : Rossi G, Ignatiadis M
Year : 2019
Journal : Cancer Res

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Authors : Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber Rd, de Azambuja E, Ignatiadis M
Year : 2019
Journal : Cancer
Volume : 125
Pages : 307-316

Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications.

Authors : Jézéquel P, Kerdraon O, Hondermarck H, Guérin-Charbonnel C, Lasla H, Gouraud W, Canon JL, Gombos A, Dalenc F, Delaloge S, Lemonnier J, Loussouarn D, Verrièle V, Campone M
Year : 2019
Journal : Breast Cancer Res
Volume : 21
Pages : 65

PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.

Authors : Tuyaerts S, Van Nuffel AMT, Naert E, van Dam PA, Vuylsteke P, De Caluwe A, Aspeslagh S, Dirix P, Lippens L, De Jaeghere E, Amant F, Vandecasteele K, Denys H
Year : 2019
Journal : BMC Cancer
Volume : 19
Pages : 506

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.

Authors : Lambertini M, Campbell C, Gelber Rd, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart-Gebhart M, Loi S, de Azambuja E
Year : 2019
Journal : Breast Cancer Res Treat

BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.

Authors : Solinas C, Marcoux D, Garaud S, Vitória JR, Van den Eynden G, de Wind A, De Silva P, Boisson A, Craciun L, Larsimont D, Piccart-Gebhart M, Detours V, Tkint de Roodenbeke D, Willard-Gallo K
Year : 2019
Journal : Cancer Lett
Volume : 450
Pages : 88-97

Orthostatic blood pressure drop and cardiovascular and psychotropic medication dosages in acutely ill geriatric inpatients.

Authors : Paul J, Vaillant F, Vanden Bossche O, Pepersack T, Henrard S, Boland B
Year : 2019
Journal : Acta Clin Belg
Pages : 1-8

Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from the NeoALTTO trial.

Authors : Di Cosimo S, Appierto V, Pizzamiglio S, Tiberio P, Iorio MV, Hilbers F, de Azambuja E, de la Pena L, Izquierdo MÁ, Huober J, Baselga J, Piccart-Gebhart M, De Braud FG, Apolone G, Verderio P, Daidone MG
Year : 2019
Journal : Clin Cancer Res

Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.

Authors : Caparica R, Bruzzone M, Poggio F, Ceppi M, de Azambuja E, Lambertini M
Year : 2019
Journal : Breast Cancer Res Treat
Volume : 174
Pages : 27-37

68Ga-PSMA-11 PET/CT in a patient with non-PSA-secreting undifferentiated prostate cancer before and after treatment with cabozantinib.

Authors : Artigas C, Plouznikoff N, Gil T, Duran Derijckere I, Herchuelz M, Libert I, Flamen P
Year : 2019
Journal : Eur J Nucl Med Mol Imaging